BG63149B1 - Употреба на флупиртин за предпазване и лечение назаболявания, свързани с увреждане на хематопоетичната клетъчна система - Google Patents

Употреба на флупиртин за предпазване и лечение назаболявания, свързани с увреждане на хематопоетичната клетъчна система Download PDF

Info

Publication number
BG63149B1
BG63149B1 BG102404A BG10240498A BG63149B1 BG 63149 B1 BG63149 B1 BG 63149B1 BG 102404 A BG102404 A BG 102404A BG 10240498 A BG10240498 A BG 10240498A BG 63149 B1 BG63149 B1 BG 63149B1
Authority
BG
Bulgaria
Prior art keywords
cells
flupirtine
treatment
apoptosis
infected
Prior art date
Application number
BG102404A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG102404A (en
Inventor
Gabriela Pergande
Werner Mueller
Original Assignee
Asta Medica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Aktiengesellschaft filed Critical Asta Medica Aktiengesellschaft
Publication of BG102404A publication Critical patent/BG102404A/xx
Publication of BG63149B1 publication Critical patent/BG63149B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG102404A 1995-11-07 1998-04-24 Употреба на флупиртин за предпазване и лечение назаболявания, свързани с увреждане на хематопоетичната клетъчна система BG63149B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19541405A DE19541405A1 (de) 1995-11-07 1995-11-07 Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
PCT/DE1996/002009 WO1997017072A2 (de) 1995-11-07 1996-10-23 Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen

Publications (2)

Publication Number Publication Date
BG102404A BG102404A (en) 1998-12-30
BG63149B1 true BG63149B1 (bg) 2001-05-31

Family

ID=7776799

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102404A BG63149B1 (bg) 1995-11-07 1998-04-24 Употреба на флупиртин за предпазване и лечение назаболявания, свързани с увреждане на хематопоетичната клетъчна система

Country Status (27)

Country Link
US (2) US6034111A (ko)
EP (1) EP0859613B1 (ko)
JP (1) JPH11514652A (ko)
KR (1) KR100512673B1 (ko)
CN (1) CN1116037C (ko)
AT (1) ATE316789T1 (ko)
AU (1) AU711207B2 (ko)
BG (1) BG63149B1 (ko)
BR (1) BR9611588A (ko)
CA (1) CA2189705C (ko)
CZ (1) CZ298115B6 (ko)
DE (2) DE19541405A1 (ko)
DK (1) DK0859613T3 (ko)
ES (1) ES2257755T3 (ko)
HK (1) HK1016508A1 (ko)
HU (1) HU225742B1 (ko)
MX (1) MX9803610A (ko)
NO (1) NO315074B1 (ko)
NZ (1) NZ330414A (ko)
PL (1) PL186537B1 (ko)
PT (1) PT859613E (ko)
RU (1) RU2200555C2 (ko)
SK (1) SK284601B6 (ko)
TW (1) TW393317B (ko)
UA (1) UA51682C2 (ko)
WO (1) WO1997017072A2 (ko)
ZA (1) ZA968783B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
EP1688141A1 (en) * 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102009023162B4 (de) * 2009-05-29 2011-07-07 Corden PharmaChem GmbH, 68305 Verfahren zur Herstellung von Flupirtin
KR101704849B1 (ko) * 2009-08-07 2017-02-08 스와겔로크 컴패니 저진공 하에서의 저온 침탄
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
MX2014010460A (es) * 2012-03-02 2014-10-13 Meda Pharma Gmbh & Co Kg Formulaciones farmaceuticas que contienen flupirtina.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN172468B (ko) * 1990-07-14 1993-08-14 Asta Medica Ag
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Also Published As

Publication number Publication date
WO1997017072A2 (de) 1997-05-15
KR19990067366A (ko) 1999-08-16
EP0859613A2 (de) 1998-08-26
PL186537B1 (pl) 2004-01-30
ES2257755T3 (es) 2006-08-01
SK58698A3 (en) 1998-09-09
BG102404A (en) 1998-12-30
NO981898D0 (no) 1998-04-27
HUP9901659A3 (en) 2001-04-28
WO1997017072A3 (de) 1997-07-24
CZ298115B6 (cs) 2007-06-27
MX9803610A (es) 1998-09-30
PT859613E (pt) 2006-06-30
DE59611327D1 (de) 2006-04-13
RU2200555C2 (ru) 2003-03-20
CA2189705C (en) 2005-08-09
PL326629A1 (en) 1998-10-12
KR100512673B1 (ko) 2005-12-09
TW393317B (en) 2000-06-11
UA51682C2 (uk) 2002-12-16
BR9611588A (pt) 1999-04-06
HUP9901659A2 (hu) 1999-09-28
CN1116037C (zh) 2003-07-30
AU711207B2 (en) 1999-10-07
DE19541405A1 (de) 1997-05-15
DK0859613T3 (da) 2006-06-06
NO981898L (no) 1998-04-27
ZA968783B (en) 1997-05-27
HU225742B1 (en) 2007-07-30
AU1716597A (en) 1997-05-29
NZ330414A (en) 1999-10-28
CN1201391A (zh) 1998-12-09
CZ128398A3 (cs) 1998-09-16
CA2189705A1 (en) 1997-05-08
HK1016508A1 (en) 1999-11-05
JPH11514652A (ja) 1999-12-14
SK284601B6 (sk) 2005-07-01
US6034112A (en) 2000-03-07
EP0859613B1 (de) 2006-02-01
NO315074B1 (no) 2003-07-07
US6034111A (en) 2000-03-07
ATE316789T1 (de) 2006-02-15

Similar Documents

Publication Publication Date Title
Antoni et al. Inhibition of apoptosis in human immunodeficiency virus-infected cells enhances virus production and facilitates persistent infection
Sarin et al. Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
US5643888A (en) Regulating retroviral replication, infection, and pathogenesis
Morris et al. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity.
Breytenbach et al. Flow cytometric analysis of the Th1–Th2 balance in healthy individuals and patients infected with the human immunodeficiency virus (HIV) receiving a plant sterol/sterolin mixture
BG63149B1 (bg) Употреба на флупиртин за предпазване и лечение назаболявания, свързани с увреждане на хематопоетичната клетъчна система
Cohen et al. Induction of theta-positive lymphocytes and lymphoblasts in mouse bone marrow by mitogens
Tian et al. HIV‐infected macrophages mediate neuronal apoptosis through mitochondrial glutaminase
JPH06504295A (ja) アンフォテリシンｂ誘導体のプロテアーゼ阻害剤としての使用
JPH11139977A (ja) Ｎｅｆ作用抑制剤
KR100294836B1 (ko) 바이러스감염증예방치료제
US6274611B1 (en) Methods and compositions for inhibition of viral replication
EP0373986A1 (fr) Composition antivirale et ses applications
IL106491A (en) A preparation based on fibuperrin for use in the treatment of the virus
Biagiotti et al. Abnormalities of in vitro immunoglobulin production in apparently healthy haemophiliacs: relationship with alterations of T cell subsets and with HTLV-III seropositivity.
Silvotti et al. FIV induced encephalopathy: early brain lesions in the absence of viral replication in monocyte/macrophages. A pathogenetic model
Nokta et al. Protein kinase C and intracellular free Ca++: relationship to human immunodeficiency virus (HIV)-induced cellular hyporesponsiveness
Gaulton et al. Inhibition of T cell antigen receptor-dependent phosphorylation of CD4 in human immunodeficiency virus type 1 infected cells.
EP0555302A1 (en) Method of treating demyelinating disease
Savarino et al. Apoptotic DNA fragmentation, and its in vitro prevention by nicotinamide, in lymphocytes from HIV‐1‐seropositive patients and in HIV‐1‐infected MT‐4 cells
JPH1045598A (ja) ウイルス感染症予防治療剤
BREYTENBACH et al. IMMUNODEFICIENCY VIRUS (HIV) RECEIVING A PLANT STEROLISTEROLIN
Kasper Mechanisms of HIV-1 Nef mediated disruption of MHC-I trafficking
JPH0892085A (ja) 抗レトロウイルス剤
ALLAVENA et al. 251. Production of multiple cytokines by clones of human large granular lymphocytes (LGL)